Albireo Pharma, Inc.
ALBO · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $448 | $600 | $316 | $287 |
| - Cash | $248 | $251 | $132 | $164 |
| + Debt | $10 | $10 | $0 | $0 |
| Enterprise Value | $210 | $358 | $184 | $123 |
| Revenue | $41 | $8 | $10 | $13 |
| % Growth | 388.4% | -13.8% | -24.4% | – |
| Gross Profit | $39 | $8 | $7 | $13 |
| % Margin | 96.7% | 100% | 77.1% | 100% |
| EBITDA | -$20 | -$96 | -$57 | -$38 |
| % Margin | -48.9% | -1,156.5% | -594.6% | -297.1% |
| Net Income | -$151 | -$119 | -$72 | -$46 |
| % Margin | -373% | -1,432.3% | -744.1% | -361.9% |
| EPS Diluted | -7.87 | -7.45 | -5.77 | -3.94 |
| % Growth | -5.6% | -29.1% | -46.4% | – |
| Operating Cash Flow | -$108 | -$101 | -$53 | -$27 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | -$108 | -$101 | -$53 | -$27 |